Macquarie Group’s Immuneering IMRX Stock Holding History

Macquarie Group’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,136	Closed	-$1.45K	–	1786
2024 Q2	$1.45K	Buy	+1,136	New	+$1.87K	﹤0.01%	1820

Other funds holding IMRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Southport Management Wilson, Wyoming $28.6M AUM 41.61% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Macquarie Group's IMRX Position: Q3 2024 in Review

Macquarie Group sold out of Immuneering (IMRX) in Q3 2024, closing a stake of 1,136 shares — an estimated $1.45K sold.

Macquarie Group first reported a position in IMRX in Q2 2024 and held it in 1 quarter. The position peaked at $1.45K in Q2 2024. 38 funds tracked by Wall St. Rank hold IMRX as of Q3 2024.

Macquarie Group reported no remaining Immuneering position as of Q3 2024 after selling out during the quarter.
Macquarie Group sold 1,136 Immuneering shares in Q3 2024, an estimated $1.45K.
Macquarie Group first reported a position in Immuneering in Q2 2024 and held it in 1 quarter.
Macquarie Group's Immuneering position peaked at $1.45K in Q2 2024.
38 funds tracked by Wall St. Rank held Immuneering as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.